Did You Know...
...that Robert Adler has the dubious distinction of being the Father of the Couch Potato? Back in 1955 Adler was employed by what was then Zenith Radio Corp., where he was charged to invent something that would allow viewers to turn down the TV volume without leaving their chairs. After a series of flops (such as a wired contraption that people tripped over), Adler hit on the idea of using sound waves. Thus the Remote Control was born...
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7563445 | CD40 binding molecules and CTL peptides for treating tumors Disclosed is a method and composition for treating tumors or infectious diseases, wherein the composition includes CD40 binding molecules together with CTL-activating peptides, e.g., tumor antigens. Such composition is useful for enhancing the anti-tumor effect of a... | 07/21/2009 |
| 7422745 | Methods of treating cancer with αβ-specific antibodies The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity αvβ3. The Vitaxin antibody consists of at least one Vitaxin heavy chain polypeptide and at least one Vitaxin light chain polypeptide ... | 09/09/2008 |
| 7422739 | Anti-CD20 antibodies Disclosed are chimeric, immunologically active, isolated, and radiolabeled antibodies directed against the CD20 antigen. The antibodies are useful for treating and diagnosing B cell disorders. ... | 09/09/2008 |
| 7422744 | Methods of treating cancer with alphavbeta3-specific antibodies The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity to αvβ3. The Vitaxin antibody consists of at least one Vitaxin heavy chain polypeptide and at least one Vitaxin light chain polypepti... | 09/09/2008 |
| 7399471 | Polypeptides capable of forming antigen binding structures with specificity for the Rhesus D antigens, the DNA encoding them and the process for their preparation and use Polypeptides capable of forming antigen binding structures specific for Rhesus D antigens include the sequences indicated in the FIGS. 1a to 16b. The obtained polypeptides, being Fab fragments, MAY be used directly as an active ingredient... | 07/15/2008 |
| 7371382 | Methods of inhibiting αβ-mediated binding with αβ-specific antibodies The invention provides enhanced LM609 grafted antibodies exhibiting selective binding affinity to αVβ3, or a functional fragment thereof. The invention also provides nucleic acid molecules encoding the enhanced LM609 grafted antibodies. Addit... | 05/13/2008 |
| 7361344 | Co-administration of a thrombolytic and an-anti-CD18 antibody in stroke A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of remova... | 04/22/2008 |
| 7361345 | Anti-CD40 antibodies capable of blocking B-cell activation Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the... | 04/22/2008 |
| 7361336 | Methods of cancer therapy targeted against a cancer stem line Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer t... | 04/22/2008 |
| 7338660 | Methods of treating cancer and enhancing immune responses with antibodies that bind CD40 The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof.... | 03/04/2008 |
| 7323171 | Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction Methods of using inhibitors of the CD2/LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in mammals, including humans. Such conditions include psoriasis, UV damage... | 01/29/2008 |
| 7323170 | Anti-CD80 antibodies The present invention relates to the identification of macaque antibodies to human B7.1 and B7.2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from B7.1 and/or B7.2 immunized monkeys. More specifically, the invention... | 01/29/2008 |
| 7309489 | Mouse CD40 ligand-specific antibodies and hybridomas There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding r... | 12/18/2007 |
| 7291330 | MD-1 inhibitors as immune suppressants Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of an agent that inhibits MD-1 with or without an OX-2 protein or a nucleic acid encoding an OX-2 protein. The methods are useful in prevent... | 11/06/2007 |
| 7288252 | Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or ... | 10/30/2007 |
| 7288251 | Antibodies to CD40 The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof.... | 10/30/2007 |
| 7276237 | Human Mob-5 (IL-24) receptors and uses thereof The present invention provides the receptors for Mob-5 (IL-24). One of the Mob-5 receptors comprises IL-22R1 and IL-20R2. Another Mob-5 receptor comprises IL-20R1 and IL-22R2. The invention also provides methods of inhibiting the Mob-5 receptor as well as methods of... | 10/02/2007 |
| 7273609 | Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNFα inhibitors by admin... | 09/25/2007 |
| 7265212 | Anti-CD45RB antibodies Antibodies which specifically recognize the human CD45 isoform RB are presented. These antibodies may be used to block undesirable immune reactions in patients with transplant rejection and autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and aut... | 09/04/2007 |
| 7259247 | Anti-human T-cell costimulating polypeptide monoclonal antibodies A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against said 8F4 molecule and hybridoma cells which produce the monoclonal antibodies, the use as medicaments of substances which inhibit the ... | 08/21/2007 |
| 7192585 | CD80 specific antibodies The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 recep... | 03/20/2007 |
| 7193064 | Anti-CD40 monoclonal antibody An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40. ... | 03/20/2007 |
| 7175847 | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 recep... | 02/13/2007 |
| 7172759 | Induction of cytotoxic T lymphocyte responses using anti-CD40 antibodies Disclosed are methods of inducing maturation of antigen presenting cells and cytotoxic T lymphocyte responses utilizing agonist anti-CD40 antibodies that do not block the binding of CD40L to CD40. ... | 02/06/2007 |
| 7169389 | Human CD154 binding molecules and treatment methods A CD154 binding molecule, in particular an antibody to human CD154, especially a human antibody to human CD154 is provided, wherein the CDRs of the heavy chain and light chain have amino acid sequences as defined, for use in the treatment and/or prevention of diseas... | 01/30/2007 |
| 7157086 | Treatment for inflammatory bowel disease with α4-specific antibodies The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel ... | 01/02/2007 |
| 7153508 | Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 recep... | 12/26/2006 |
| 7147851 | Humanized immunoglobulin reactive with α4β7 integrin The present invention relates to humanized immunoglobulins having binding specificity for α4β7 integrin, comprising an antigen binding region of nonhuman origin (e.g., rodent) and at least a portion of an immunoglobulin of human origin (e.g., a human framework reg... | 12/12/2006 |
| 7132099 | Methods of modulating T lymphocyte costimulation with an antibody to an 8F4 polypeptide A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against said 8F4 molecule and hybridoma cells which produce the monoclonal antibodies, the use as medicaments of substances which inhibit the ... | 11/07/2006 |
| 7125553 | Methods of inducing immune tolerance using immunotoxins Provided is a method of treating an immune system disorder not involving T cell proliferation, comprising administering to the animal an immunotoxin comprising a mutant diphtheria toxin moiety linked to an antibody moiety which routes by the anti-CD3 pathway, or der... | 10/24/2006 |
| 7125551 | Methods for treatment of asthmatic disorders using a monoclonal antibody to 8F4 polypeptide The present invention relates to methods and compositions for the prevention and treatment and prevention of immune system disorders, including cancer, AIDS, asthmatic disorders, autoimmune diseases, organ transplant rejection and chronic viral diseases such as HCV ... | 10/24/2006 |
| 7122187 | Treating autoimmune diseases with humanized anti-CD40L antibody The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases; and an immunosuppressant during transplantation of heterologou... | 10/17/2006 |
| 7122183 | Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNFα inhibitors by admin... | 10/17/2006 |
| 7118743 | Bispecific molecules cross-linking ITIM and ITAM for therapy The invention includes bispecific molecules capable of cross-linking ITAM and ITIM receptors on a cell in order to inhibit cell activation, as well as gene therapy approaches using nucleotides encoding such bispecific molecules for expression in vivo. One example of... | 10/10/2006 |
| 7094404 | Method for treating malignancy and autoimmune disorders in humans using tac antibodies The present invention relates to a method for treating conditions associated with elevated levels of Tac-positive cells, including malignancy and autoimmune disorders and for preventing allograft rejection. 90Y-Conjugated anti-Tac or Ricin A conjugated an... | 08/22/2006 |
| 7083785 | Methods of treatment by administering an anti-BCMA antibody A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided. ... | 08/01/2006 |
| 7074403 | Immunotherapy of autoimmune disorders using antibodies which target B-cells Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produ... | 07/11/2006 |
| 7074406 | Treating allergic diseases with humanized anti-CD40L antibody The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases. ... | 07/11/2006 |
| 7070776 | Methods for blocking binding of CD28 receptor to B7 The invention identifies the B7 antigen as a ligand that is reactive with the CD28 receptor on T cells. The invention further provides methods for using antibodies to B7, or fragments thereof, to regulate CD28 positive T cell response and immune responses mediated b... | 07/04/2006 |
| 7067132 | Antagonists of interleukin-15 Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15Rα-subunit and that are incapable of transducing a signal through either the β- or γ-subunit... | 06/27/2006 |
